Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer | News | Anocca
Summary
Anocca raised about SEK 440 million to fund continued development of its VIDAR-1 program for pancreatic cancer. The company will use the capital to advance early-stage clinical trials and support its preclinical pipeline. Recruitment is now open for the Phase I multi-centre trial across Sweden, Denmark, Germany, and the Netherlands. Anocca also highlighted its proprietary discovery platform, in-house manufacturing capability, and custom software ecosystem as part of its clinical development approach.
Funding
Amount
$46.0M
Total raised
Date
August 18, 2025
Announcement date
Investors
-
Lead investors
Company
anocca.com
Funded company
Classifications
industries
Engineering
applications
Web and Content Management
AskAI Classifications
Labels
Biotech Software
Computational Biology
Developer Tools
Linked Companies
Anocca
$10M to $25M